Monograph
C09BA06 - Quinapril and Diuretics |
Propably not porphyrinogenic |
PNP |
Rationale
quinapril: No evidence of CYP-dependent metabolism. Hydrochlorthiazide: Not metabolised. Probably no CYP-affinity. Clinical experience of non-porphyrinogenicity. Conflicting evidence.
Chemical description
quinapril: HCl-salt of quinapril, which is a prodrug of the metabolite quinaprilate is excreted unchanged by the kidneys. Hydrochlorthiazide: thiazide diuretic, sulfonamide congener. Eliminated in urine in unchanged form. Probably no CYP-affinity. Hydrochlorthiazide: South African list: use. French list: authorized. Australian list: unsafe associated with attacks. Thunell, patient report (n=1): tolerated. Andersson, patient reports (n=10): tolerated. Martindale: Hydrochlorthiazide has been associated with acute attacks of porphyria and is considred unsafe in porphyric patients. EPI-list: sulfonamides are on the unsafe list.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
United Kingdom
Latvia© NAPOS 2024